Lyra Therapeutics (LYRA) Accumulated Depreciation (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Accumulated Depreciation for 7 consecutive years, with $4.5 million the latest figure, recorded in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $4.5 million, up 10.17% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 million (up 10.17% YoY), and the FY2025 annual result was $4.5 million, up 10.17% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $4.5 million, up from $4.4 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $4.7 million in Q3 2022, with the low at $1.9 million in Q4 2023.
• A 5-year average of $3.7 million and a median of $4.1 million in 2022 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation sank 53.98% in 2023 and jumped 114.94% in 2024, its largest moves.
• Lyra Therapeutics' Accumulated Depreciation stood at $3.9 million in 2021, then advanced by 7.61% to $4.2 million in 2022, then sank by 53.98% to $1.9 million in 2023, then jumped by 114.94% to $4.1 million in 2024, then advanced by 10.17% to $4.5 million in 2025.
• The last three Accumulated Depreciation figures came in at $4.5 million (Q4 2025), $4.4 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.